Download PDF BrochureInquire Before Buying
The Canada Preimplantation Genetic Testing (PGT) Market involves specialized testing used during in vitro fertilization (IVF) to check embryos for genetic abnormalities or specific hereditary diseases before they are transferred to the uterus. Essentially, this technology helps prospective parents increase the chance of a successful pregnancy and have a child free from serious genetic conditions by identifying healthy embryos. This market is driven by increasing adoption in fertility clinics across Canada as genetic science and screening technology become more advanced and reliable.
The Preimplantation Genetic Testing Market in Canada is anticipated to grow steadily at a CAGR of XX% from 2025 to 2030, rising from an estimated US$ XX billion in 2024–2025 to US$ XX billion by 2030.
The global preimplantation genetic testing market is valued at $636.4 million in 2024, projected to reach $690.2 million in 2025, and is expected to hit $1,135.0 million by 2030, growing at a CAGR of 10.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Drivers
The Canada Preimplantation Genetic Testing (PGT) Market is primarily driven by the rising adoption of In Vitro Fertilization (IVF) procedures across the country, fueled by increasing rates of infertility attributed to factors like delayed parenthood and lifestyle changes. PGT, encompassing Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS), offers couples undergoing IVF the ability to test embryos for specific genetic disorders (PGD) or chromosomal abnormalities (PGS) before implantation, thereby increasing the success rate of IVF cycles and reducing the risk of miscarriage or passing on genetic diseases. Furthermore, the growing awareness and acceptance of PGT among fertility specialists and the general public in Canada contributes significantly to market expansion. Governmental support and funding in certain provinces for IVF, as mentioned in external sources, implicitly supports PGT adoption by increasing access to the prerequisite procedure. The increasing age of the maternal population in Canada, which correlates with a higher risk of aneuploidy (chromosomal abnormalities), acts as a major demographic driver for Preimplantation Genetic Screening (PGS). Lastly, technological advancements in genetic sequencing and testing methodologies, such as Next-Generation Sequencing (NGS) for comprehensive chromosome screening, are enhancing the accuracy and accessibility of PGT, making it a more reliable and desirable option for prospective parents.
Restraints
Despite its clinical benefits, the Canadian PGT Market faces notable restraints, chiefly revolving around the high cost of the procedure and limited public funding. PGT is an expensive add-on to the already costly IVF process, which often acts as a significant financial barrier for many couples seeking treatment, particularly since provincial funding for PGT remains inconsistent and restricted. Regulatory and ethical complexities also pose a constraint; while PGT is generally permitted, ongoing societal debates concerning embryo selection and disposal, as well as the regulation of novel genetic testing platforms, can slow down market growth and clinical adoption. Another significant restraint is the invasive nature of the embryo biopsy required for PGT, which, although generally safe, carries a marginal risk of damage to the embryo, leading to concerns among patients and clinicians regarding viability. There is also a shortage of specialized genetic counselors and embryologists trained specifically in advanced PGT techniques, limiting the capacity of some fertility clinics to offer comprehensive services. Furthermore, the variability in clinical guidelines and standardized protocols across different provinces and clinics can create confusion and hinder the uniform integration of PGT technologies into routine clinical practice throughout Canada.
Opportunities
The Canadian Preimplantation Genetic Testing Market presents substantial opportunities for growth, particularly through technological innovation and expanding applications. A major opportunity lies in the shift towards non-invasive PGT (niPGT), which aims to analyze cell-free DNA released by the blastocyst into the culture medium instead of requiring a direct embryo biopsy. If clinically validated, niPGT could dramatically reduce risk and accelerate adoption rates. The market also has a strong opportunity in expanding the scope of testing beyond aneuploidy screening to include monogenic disorders, Human Leukocyte Antigen (HLA) typing, and potentially even polygenic risk scores for complex adult-onset diseases, subject to ethical review. Moreover, increasing patient education and awareness campaigns, supported by professional organizations and clinics, can bridge the gap in understanding and acceptability, thereby increasing market penetration. Strategic partnerships between Canadian fertility clinics and centralized, high-throughput genetic testing laboratories offer an opportunity for economies of scale, potentially lowering the cost per test and making PGT more affordable. Addressing the underserved population in remote and rural areas through centralized lab services supported by advanced logistics represents a key area for market expansion, leveraging Canada’s need for accessible specialized healthcare services.
Challenges
Several critical challenges impede the smooth expansion of the Canadian PGT Market. The primary technical challenge is ensuring the consistent accuracy and reliability of results, as mosaicism (the presence of two or more cell lines with different genetic makeups in the same embryo) can lead to inconclusive results and complex counseling issues, impacting clinical decision-making. Standardizing embryo biopsy techniques and genetic analysis protocols across different clinics remains a logistical and quality control challenge. Furthermore, the Canadian healthcare system’s fragmented nature, with differing provincial approaches to funding and coverage for IVF and PGT, creates a market access challenge, resulting in unequal distribution of these advanced reproductive technologies. Data privacy and security, governed by strict Canadian privacy laws, present challenges related to the storage, sharing, and interpretation of highly sensitive genetic data generated during PGT. Another challenge is the need for continuous professional development and training for clinical staff to keep pace with the rapidly evolving genetic sequencing technologies and interpretation models. Finally, the ethical scrutiny surrounding the potential for “designer babies” and the selection of non-medical traits requires careful navigation and robust national ethical frameworks to maintain public trust and regulatory compliance.
Role of AI
Artificial Intelligence (AI) is poised to revolutionize the Canadian Preimplantation Genetic Testing Market by significantly enhancing efficiency and accuracy at multiple stages. In the laboratory, AI can be utilized to automate and optimize image analysis during the embryo selection process, complementing or potentially replacing manual grading based on morphological criteria, thus reducing inter-operator variability and improving the prediction of implantation success. AI and Machine Learning (ML) algorithms are crucial for interpreting complex genetic sequencing data generated by PGT, particularly in resolving cases of suspected embryonic mosaicism by analyzing sequencing reads and distinguishing biological noise from true genetic variants with greater precision. Furthermore, AI can aid in quality control during the testing workflow by identifying technical errors and minimizing sample handling variability, ensuring higher quality results. AI-powered clinical decision support systems offer significant potential by integrating patient history, IVF cycle data, and PGT results to provide personalized recommendations to clinicians and genetic counselors, optimizing treatment plans. Ultimately, the application of AI will streamline the PGT process, improve the cost-effectiveness of testing by reducing human error and time, and thus directly support the market’s goal of achieving higher, more predictable IVF success rates.
Latest Trends
The Canadian PGT Market is being shaped by several cutting-edge trends reflecting advancements in reproductive genetics. The shift toward blastocyst-stage biopsy over cleavage-stage biopsy is becoming the standard practice, as it provides more cells for testing and is considered to offer more reliable genetic material, often aligning with better IVF outcomes. Another key trend is the increasing adoption of Next-Generation Sequencing (NGS) as the primary platform for PGT, largely replacing older methods like Fluorescence In Situ Hybridization (FISH) and array Comparative Genomic Hybridization (aCGH), due to NGS’s higher resolution, throughput, and ability to detect segmental aneuploidies and potentially mosaicism. The growth of specialized PGT laboratories offering centralized, high-volume testing is a continuing trend, allowing clinics to focus on IVF procedures while outsourcing complex genetic analysis. Moreover, the exploration and development of Preimplantation Genetic Testing for Polygenic Risk Scores (PGT-P) is an emerging, albeit controversial, trend. PGT-P aims to screen embryos for risks associated with common complex conditions like diabetes or heart disease, opening new ethical and clinical dialogues. Lastly, there is a sustained emphasis on improving laboratory automation and microfluidic technologies to standardize and scale up sample preparation and processing, which promises to drive down costs and enhance the overall efficiency of PGT services in Canada.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605